# The Exploration of Therapeutic Antivirals for Human Papillomavirus in the Last 40 Years: Bibliometric Research

## TL;DR

This paper reviews 40 years of research on antivirals for HPV, highlighting gaps and trends to guide future treatments for HPV-related cancers.

## Contribution

The study provides a comprehensive bibliometric analysis of HPV antiviral research trends over four decades.

## Key findings

- Current research on HPV antivirals covers a wide range of pathways but lacks systematic studies.
- Prophylactic vaccines are effective, but antiviral treatments for existing infections remain underdeveloped.
- Bibliometric analysis reveals research trends that can inform future therapeutic strategies.

## Abstract

Human papillomavirus (HPV) is a well-known carcinogenic DNA virus, responsible for about 4% of all cancer cases globally. Effective antiviral treatments for those who are already infected with HPV are still in their early stages, despite the fact that prophylactic vaccinations have shown impressive success in preventing new infections. Effective treatments for HPV-related malignancies are also hampered by the fact that current articles address a wide spectrum of pathways but lack thorough systematic studies. In this work, we use bibliometric techniques to examine research trends and innovative approaches in the development of HPV antivirals over the last 40 years. Our results are intended to offer insightful information and direct future research into effective antiviral treatments for HPV-induced cancers.